menu ☰
menu ˟

An introduction to extended-release injectable naltrexone for the treatment of people with opioid dependence.

Creator:

Substance Abuse and Mental Health Services Administration

Type: Article
Region: Republic of Ireland
Northern Ireland
Description:

The US Food and Drug Administration (FDA) approved extended-release injectable naltrexone (Vivitrol) in October 2010 to treat people with opioid dependence. This medication provides patients with opioid dependence the opportunity to take effective medication monthly, as opposed to the daily dosing required by other opioid dependence medications (i.e., methadone, buprenorphine, oral naltrexone). Extended-release injectable naltrexone was approved by FDA in 2006 to treat people with alcohol dependence. This US Advisory provides behavioral health professionalsâ?"including substance abuse treatment specialistsâ?"and primary care medical providers (who treat people with opioid dependence) with an introduction to extended-release injectable naltrexone. It includes succinct information about extended-release injectable naltrexone, how it compares with other medication-assisted treatment (MAT) options, and clinical strategies that may be used to select, initiate, and administer treatment.

Date:

01/01/2012

Rights: Public
Suggested citation:

Substance Abuse and Mental Health Services Administration. (2012) An introduction to extended-release injectable naltrexone for the treatment of people with opioid dependence. [Online]. Available from: http://publichealthwell.ie/node/553632 [Accessed: 17th September 2019].

  

View your saved citations and reading lists

Contributor:

National Drugs Library
 
Click here to view all the resources gathered from this organisation's website.